Sunesis Pharmaceuticals, Inc.
395 Oyster Point Boulevard
Suite 400
South San Francisco
California
94080
United States
Tel: 650-266-3500
Fax: 650-266-3501
Website: http://www.sunesis.com/
Email: jobs@sunesis.com
About Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other unmet medical needs. We have built our product candidate portfolio through internal discovery and the in-licensing of novel cancer therapeutics. We are advancing our product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. We believe the quality and breadth of our product candidate pipeline, platform technology, strategic collaborations and scientific team will enable us to become a fully integrated biopharmaceutical company with a diversified portfolio of novel therapeutics for major diseases.
We are advancing three proprietary oncology product candidates, SNS-595, SNS-032 and SNS-314, through in-house research and development efforts. All three are inhibitors of the cell division process, known as cell-cycle inhibitors, intended for the treatment of cancer. Our lead product candidate, SNS-595, is a novel cytotoxic. Sunesis is currently conducting three Phase 2 clinical trials with its lead product candidate, SNS-595 in non-small-cell lung cancer, small-cell lung cancer and ovarian cancer. A Phase 1 clinical trial in patients with advanced acute leukemias is underway; a second Phase 1 trial is being planned with SNS-595 in combination with Ara-C in patients with advanced acute leukemias. A second product being developed clinically is SNS-032, which is in one Phase 1/2 clinical study in patients with advanced solid tumors, and a second Phase 1 is being planned in patients with advanced B-lymphoid malignancies. Sunesis is also developing SNS-314, which is expected to enter Phase 1 clinical trials in early 2007. The company holds worldwide development and commercialization rights to SNS-595, SNS-032 (for diagnostic and therapeutic applications) and SNS-314, the Aurora kinase inhibitor program.
We have developed a proprietary method of discovering drugs in pieces, or fragments. We call this fragment-based discovery approach ''Tethering®''. Tethering® is a process whereby a target protein known to be involved in a disease process is engineered to facilitate the binding of small drug fragments. Once a small fragment is identified, the fragment is built out using the target protein's surface as a template to make a new full-size therapeutic compound. We combine Tethering® with other drug discovery tools, such as structure-based design and medicinal chemistry, to discover and develop novel therapeutics for major diseases. In addition to its use in our internal drug discovery efforts, Tethering® is the basis of our four strategic collaborations with Biogen Idec, Johnson & Johnson PRD and Merck. Since June 2004, each of our current collaboration partners has either extended its existing collaboration or entered into a new collaboration with our company. We believe that our strategic collaborations will enable us to leverage and expand our internal development capabilities, manage our cash expenditures and diversify risk across our pipeline.
Last Updated: 01-09-2007
370 articles about Sunesis Pharmaceuticals, Inc.
-
Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement
11/30/2020
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) and Viracta Therapeutics, Inc., a privately held precision oncology company targeting virus-associated malignancies, today announced they have entered into a definitive merger agreement (the “Merger Agreement”) pursuant to which Viracta will combine with Sunesis in an all-stock transaction (the “Merger”).
-
Sunesis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Recent HighlightsSunesis to Host Conference Call Today at 4:30 PM Eastern Time
11/16/2020
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the third quarter ended September 30, 2020. Loss from operations for the three months ended September 30, 2020 was $4.5 million
-
Sunesis Pharmaceuticals to Host Conference Call on November 16th to Discuss Third Quarter 2020 Financial Results and Recent Highlights
11/9/2020
Sunesis Pharmaceuticals, Inc. announced that it will host a conference call on Monday, November 16th, 2020 at 4:30pm Eastern Time to discuss corporate updates and financial results for the third quarter ended September 30, 2020.
-
Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
10/12/2020
Sunesis Pharmaceuticals, Inc. announced a poster presentation at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held October 24-25, 2020 in a virtual format.
-
Sunesis Pharmaceuticals Announces Participation at Upcoming Investor Conferences - Sep 03, 2020
9/3/2020
Sunesis Pharmaceuticals, Inc. announced that the Company will present at two upcoming virtual investor conferences.
-
Sunesis Pharmaceuticals Announces 1-for-10 Reverse Stock Split
9/2/2020
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-10 reverse stock split, effective as of 5:00 p.m. Eastern Time today.
-
Sunesis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Recent HighlightsSunesis to Host Conference Call Today at 4:30 PM Eastern Time
8/11/2020
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the second quarter ended June 30, 2020. Loss from operations for the three months ended June 30, 2020 was $6.3 million.
-
Sunesis Pharmaceuticals to Host Conference Call on August 11th to Discuss Second Quarter 2020 Financial Results and Recent Highlights
8/4/2020
Sunesis Pharmaceuticals, Inc. announced that it will host a conference call on Tuesday, August 11th, 2020 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended June 30, 2020.
-
Sunesis Announces Pricing of $12 Million Offering of Common Stock
7/29/2020
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the pricing of an underwritten public offering of 52,173,913 shares of its common stock. The public offering price of each share of common stock is $0.23. Sunesis expects to receive gross proceeds of approximately $12 million from this offering, before deducting the underwriting discounts and estimated offering expenses. Sunesis has granted the underwriters a 30-day opti
-
Sunesis Announces Proposed Public Offering of Common Stock
7/28/2020
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock, in an underwritten public offering
-
Sunesis Pharmaceuticals Provides Corporate UpdateCompany reduces workforce to focus on development of PDK1 inhibitor, SNS-510
7/7/2020
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a reduction in workforce of approximately 30% of its head count to focus on development of its first-in-class PDK1 inhibitor SNS-510.
-
Sunesis Pharmaceuticals Announces Clinical Update on Vecabrutinib ProgramCompany Shifting Resources from Vecabrutinib to Development of PDK-1 Inhibitor SNS-510
6/23/2020
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will not advance its non-covalent BTK inhibitor vecabrutinib into the planned Phase 2 portion of the Phase 1b/2 trial in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The decision was made after assessing the totality of the data including the 500 mg cohort, the highest dose studied in the trial. “Alth
-
Sunesis Pharmaceuticals Reports First Quarter 2020 Financial Results and Recent HighlightsSunesis to Host Conference Call Today at 4:30 PM Eastern Time
5/7/2020
Sunesis Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2020.
-
Sunesis Pharmaceuticals to Host Conference Call on May 7th to Discuss First Quarter 2020 Financial Results and Recent Highlights
4/30/2020
Sunesis Pharmaceuticals, Inc. announced that it will host a conference call on Thursday, May 7th, 2020 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2020.
-
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Recent HighlightsSunesis to Host Conference Call Today at 4:30 PM Eastern Time
3/10/2020
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the fourth quarter and year ended December 31, 2019. Loss from operations for the three months and year ended December 31, 2019 was $5.4 million and $23.3 million.
-
Sunesis Pharmaceuticals to Host Conference Call on March 10th to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Highlights
3/3/2020
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, March 10, 2020 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2019.
-
Sunesis Pharmaceuticals to Present at the 40th Annual Cowen Health Care Conference
2/25/2020
Sunesis Pharmaceuticals, Inc. announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the 40th Annual Cowen Health Care Conference on Tuesday, March 3, 2020 at 10:00 AM Eastern Standard Time in Boston, Massachusetts.
-
Denovo Biopharma Licenses Global Rights to a Novel Late-Stage Oncology Drug from Sunesis Pharmaceuticals
12/6/2019
Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it has licensed its fifth late-stage drug asset: Vosaroxin from Sunesis Pharmaceuticals.
-
Sunesis Pharmaceuticals Announces Data from Ongoing Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell MalignanciesPoster to be Presented at Upcoming ASH Annual Meeting
12/5/2019
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced data from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies.
-
Sunesis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Highlights
11/12/2019
Phase 1b/2 Trial of Vecabrutinib in 400 mg Cohort; Clinical Update at Upcoming ASH Annual Meeting